What biomarker testing is recommended for locally advanced Melanoma

Biomarker Testing for Locally Advanced Melanoma

Based on the NCCN Guidelines for Patients: Melanoma (2025), here's what you should know about biomarker testing for locally advanced (stage 3) melanoma:

Key Biomarker Tests Recommended

BRAF Mutation Testing (Primary Priority)

This is the most important biomarker test for locally advanced melanoma. According to NCCN Guidelines, BRAF mutation testing should be performed because:

• BRAF mutations are abnormal changes in a specific gene that can cause normal skin cells to become cancerous
• If you have a BRAF V600 mutation, this opens up targeted therapy options (like dabrafenib/trametinib combinations) that specifically attack cancer cells with this mutation
• This test helps your oncologist determine which treatment approaches may work best for your specific cancer

Other Genetic Testing

The NCCN Guidelines note that testing for CDKN2A mutations (also called p16INK4A or MTS1) may be considered, as this is the most common gene mutation found in melanoma patients.

Why This Matters for Your Treatment

Understanding your biomarker status is crucial because:

• If BRAF-positive: You may be eligible for targeted therapy drugs that specifically block the BRAF mutation
• If BRAF-negative: Your care team will focus on immunotherapy options (like nivolumab or pembrolizumab) or other systemic treatments
• Genetic counseling: If testing reveals hereditary cancer patterns, you may be referred for genetic counseling

Questions to Ask Your Oncology Team

1. Have I been tested for BRAF mutations? If not, why not?
2. What were my specific biomarker results, and what do they mean for my treatment options?
3. Should I have additional genetic testing (like CDKN2A)?
4. Based on my biomarker status, which treatment approaches do you recommend?
5. Are there clinical trials available that target my specific biomarkers?

Important Context

According to NCCN Guidelines, biomarker testing helps guide treatment decisions for locally advanced melanoma, particularly when considering:

• Neoadjuvant systemic therapy (treatment before surgery to shrink tumors)
• Adjuvant therapy (treatment after surgery to reduce recurrence risk)
• Targeted therapy vs. immunotherapy approaches

Your oncologist will use these biomarker results along with your complete clinical picture—including tumor stage, location, and other factors—to determine the most appropriate treatment strategy for your specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.